1. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement.
Stergiou GS, Palatini P, Parati G, O'Brien E, Januszewicz A, Lurbe E, Persu A, Mancia G, Kreutz R.
+ View Abstract
Lucas Aparicio (Argentina), Kei Asayama (Japan), Roland Asmar (France), Grzegorz Bilo (Italy), Jean-Marc Boivin (France), Alejandro de la Sierra (Spain), Eamon Dolan (Ireland), Jan Filipovsky (Czech Republic), Geoffrey Head (Australia), Yutaka Imai (Japan), Kazuomi Kario (Japan), Anastasios Kollias (Greece), Efstathios Manios (Greece), Klaus Matthias (Germany), Richard McManus (UK), Anastasia Mihailidou (Australia), Paul Muntner (USA), Martin Myers (Canada), Teemu Niiranen (Finland), Angeliki Ntineri (Greece), Takayoshi Ohkubo (Japan), Aleksander Prejbisz (Poland), Athanase Protogerou (Greece), Menno Pruijm (Switzerland), Aletta Schutte (Australia), Daichi Shimbo (USA), Joseph Schwartz (USA), James Sharman (Australia), Andrew Shennan (UK), Jan Staessen (Belgium), Markus van der Giet (Germany), Liffert Vogt (The Netherlands), Jiguang Wang (China), Paul Whelton (USA), William White (USA).
|
2. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight.
+ View Abstract
From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia and sub-Saharan Africa, the underweight tail of the BMI distribution was left behind as the distribution shifted. There is a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions.
|
3. Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension.
Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, Steckelings UM, Stergiou G, Tomaszewski M, Unger T, Wainford RD, Williams B, Rodgers A, Schutte AE.
|
4. Blood pressure and outcome in patients with atrial fibrillation: floating in uncharted waters.
Kyriakoulis KG, Kollias A, Stergiou GS.
|
5. Reproducibility of Office and Out-of-Office Blood Pressure Measurements in Children: Implications for Clinical Practice and Research.
Stergiou GS, Bountzona I, Alamara C, Vazeou A, Kollias A, Ntineri A.
+ View Abstract
This study aimed to evaluate the reproducibility of office (OBP), ambulatory (ABP), and home blood pressure (HBP) measurements in children and adolescents, and their implications in diagnosing hypertension in clinical practice and in pediatric hypertension research. Apparently healthy children and adolescents referred for suspected hypertension were included. Measurements of 2-visit OBP, 7-day HBP, and 24-hour ABP were performed twice, 1 to 6 months apart. Reproducibility was quantified using the SD of differences between repeated measurements. The sample size of clinical trials comparing the efficacy of antihypertensive drugs using each method was calculated. Fifty-eight individuals were analyzed (mean age, 13.0±2.9 years, 60.3% boys). The reproducibility of 24-hour ABP (SD of differences 5.7/4.5 systolic/diastolic) and HBP (5.9/5.0 mm Hg) were comparable and superior to that of visit-2 OBP (9.2/7.8) and awake (6.7/5.5) or asleep ABP (7.6/6.1). As a consequence, a parallel-group comparative trial aiming to detect a difference in the effect of 2 drugs of 10 mm Hg systolic BP, would require 36 participants when using OBP measurements, 14 using 24-hour ABP, and 15 using HBP (102/34/42 respectively for detecting a 5 mm Hg difference in diastolic BP). For a crossover design trial, the corresponding sample sizes are 9/3/4 for systolic BP and 26/9/11 for diastolic, respectively. These data suggest that in children and adolescents 24-hour ABP and 7-day HBP have similar reproducibility, superior to OBP and daytime or asleep ABP. These findings have major implications in diagnosing hypertension in children in clinical practice and in designing clinical research trials in pediatric hypertension.
|
6. Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?
Kollias A, Kyriakoulis KG, Syrigos NK, Stergiou GS.
|
7. Anticoagulant selection in relation to the SAMe-TT
Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, Thompson M, Lip GYH, Olshansky B.
|
8. Validation of the single-cuff oscillometric blood pressure monitor InBody BPBIO750 for public spaces according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization Universal Standard.
Ntineri A, Prapa S, Bountzona I, Menti A, Stergiou GS.
|
9. The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension.
|
10. Prevalence, awareness, treatment and control of hypertension in Greece: EMENO national epidemiological study.
Stergiou GS, Menti A, Kalpourtzi N, Gavana M, Vantarakis A, Chlouverakis G, Hajichristodoulou C, Trypsianis G, Voulgari PV, Alamanos Y, Karakosta A, Touloumi G.
|
11. Clinical hypertension research in patients with atrial fibrillation: At last!
Kollias A, Kyriakoulis KG, Stergiou G.
|
12. Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants.
|
13. High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey.
Touloumi G, Karakosta A, Kalpourtzi N, Gavana M, Vantarakis A, Kantzanou M, Hajichristodoulou C, Chlouverakis G, Trypsianis G, Voulgari PV, Alamanos Y, Makrilakis K, Liatis S, Chatzipanagiotou S, Stergiou G.
|
14. Automated blood pressure measurement in atrial fibrillation: validation process modification and evaluation of a novel professional device which detects atrial fibrillation and adapts its blood pressure measurement algorithm.
Stergiou GS, Kyriakoulis KG, Bountzona I, Menti A, Destounis A, Kalogeropoulos P, Kollias A.
|
15. Reply.
Schlaich MP, Borghi C, Tomaszewski M, Stergiou GS, Schutte AE, Unger T.
|
16. Blood pressure measurement methodology and technology in the SWEET diabetes centers: An international SWEET database survey.
Gerasimidi-Vazeou A, Birkebaek NH, Iotova V, Cherubini V, Piccini B, Biester T, Stipancic G, Jefferies C, Maffeis C, Stergiou GS.
|
17. Twenty-four-hour ambulatory central blood pressure in adolescents and young adults: association with peripheral blood pressure and preclinical organ damage.
Ntineri A, Kollias A, Bountzona I, Servos G, Moyssakis I, Destounis A, Vazeou A, Soldatou A, Stergiou GS.
|
18. May Measurement Month 2018: results of blood pressure screening from 41 countries.
Poulter NR, Borghi C, Burger D, Castillo RR, Damasceno A, Ito S, Jose AP, Kruger R, Morgan T, Nilsson PM, Schlaich MP, Schutte AE, Stergiou G, Unger T, Wainford RD, Beaney T.
|
19. Functional and Radiological Assessment After Preservation Rhinoplasty - A Clinical Study.
Stergiou G, Tremp M, Finocchi V, Saban Y.
|
20. Insight into the 24-hour ambulatory central blood pressure in adolescents and young adults.
Ntineri A, Kollias A, Zeniodi ME, Vazeou A, Soldatou A, Stergiou GS.
+ View Abstract
This study attempted to investigate the behavior of 24-hour central ambulatory blood pressure (ABP) in adolescents and young adults. Adolescents and young adults (age 10-25 years) referred for elevated blood pressure (BP) and healthy volunteers had simultaneous 24-hour peripheral (brachial) and central (aortic) ABP monitoring using the same automated upper-arm cuff device (Mobil-O-Graph 24h PWA). Central BP was calculated by the device using two different calibration methods (C1SBP using peripheral systolic (pSBP)/diastolic BP and C2SBP using mean arterial/diastolic BP). A total of 136 participants (age 17.9 ± 4.7 years, 54% adolescents, 77% males, 25% volunteers, 34% with elevated peripheral ABP) were analyzed. Twenty-four-hour pSBP was higher than C1SBP, with this difference being more pronounced during daytime than nighttime (16.3 ± 4.5 and 10.5 ± 3.2 mm Hg, respectively, P < .001). Younger age, higher body height, and male gender were associated with greater systolic ABP amplification (pSBP-C1SBP difference). C1SBP followed the variation pattern of pSBP, yet with smaller nighttime dip (8.4 ± 6.0% vs 11.9 ± 4.6%, P < .001), whereas C2SBP increased (2.4 ± 7.2%) during nighttime sleep (P < .001 for comparison with pSBP change). Older age remained independent determinant of larger nighttime BP fall for pSBP and C1SBP, whereas male gender predicted a larger nighttime C2SBP rise. These data suggest that the calibration method of the BP monitor considerably influences the diurnal variation in central BP, showing a lesser nocturnal dip than pSBP or even nocturnal BP rise, which are determined by the individual's age and gender.
|